- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Plymouth Meeting Today
By the People, for the People
INOVIO to Present at Hemophilia Conference
The biotech company will showcase its DNA-based protein replacement therapy at the World Federation of Hemophilia World Congress.
Apr. 2, 2026 at 6:35am
Got story updates? Submit your updates here. ›
INOVIO, a Pennsylvania-based biotechnology company focused on developing DNA medicines, announced that it will participate in the upcoming World Federation of Hemophilia World Congress in Kuala Lumpur. The company will present on its DNA-Encoded Protein (DPROT) technology, which has demonstrated the ability to produce functional Factor VIII protein in mouse models of hemophilia A.
Why it matters
INOVIO's DPROT platform represents a potential non-viral, gene-based approach to treating hemophilia, a rare genetic disorder characterized by excessive bleeding. If successful, this technology could provide an alternative to traditional protein replacement therapies, which require frequent intravenous infusions.
The details
At the conference, INOVIO will give a presentation on its DPROT technology and its ability to express Factor VIII protein in vivo. The company will also present a poster detailing the results of its studies in hemophilia A mouse models, which showed that the DPROT platform was able to produce efficacious levels of Factor VIII and correct the bleeding phenotype.
- The World Federation of Hemophilia World Congress will take place from April 20-24, 2026 in Kuala Lumpur, Malaysia.
- INOVIO's presentation is scheduled for Wednesday, April 22 at 9:45 AM MYT.
- INOVIO's poster presentation is also scheduled for Wednesday, April 22 at 10:45 AM MYT.
The players
INOVIO
A biotechnology company focused on developing and commercializing DNA medicines to treat and protect people from HPV-related diseases, cancer, and infectious diseases.
What’s next
INOVIO plans to share the available abstracts from its presentations on the company's website following the conference.
The takeaway
INOVIO's participation in the World Federation of Hemophilia World Congress highlights the potential of its DNA-based protein replacement therapy to provide a novel treatment option for patients with hemophilia A, a debilitating genetic disorder.
